



ISPOR Russia HTA Chapter Meeting

«Perspectives of development of health technology assessment principles in Russia by the example of the Russian Federation Government decree №871»

ISPOR 18th Annual European Congress

16:30-18:30, Monday, November 9th, 2015

Milano Congressi, Room: Amber 5-6 (L2)

Milan, Italy

Moderator:

Vitaly Omelyanovskiy, MD, PhD, DSc, Professor, President, ISPOR Russia HTA Chapter, Director, FSBI «Center of Expertise and Quality Control of Medicines» of the Ministry of health of the Russian Federation, Director, Center for Health Technology Assessment (HTA), Russian Presidential Academy of National Economy and Public Administration (RANEPA)

Attendees:

ISPOR Russia HTA Chapter Members and invitees

Invited Guests:

Vladimir Zah, PhD, Chair, ISPOR CEE Network Executive Committee

Alexey Kolbin, MD, PhD, DSc, Professor, President, ISPOR Russia St. Petersburg Chapter

Vladimir Matveev, MD, Professor, President of ISPOR Belarus Chapter

Olha Zaliska, PharmD, PhD, Professor, President, ISPOR Ukraine Chapter

Alexander Kostyuk, PhD, Professor, President, ISPOR Kazakhstan Chapter

ISPOR Regional Development Staff:

Zandra Z. Yin, MA, MPA, Director, International Development (Asia, Pacific, Africa & Europe)

Nadia Maldonado, Assistant Manager, International Development

Malgorzata Juszczak-Punwaney, MA, Senior Manager, Europe, Africa & Western Asia Development

AGENDA

TIME	TOPIC	PRESENTER(s)
16:30-16:40	Opening remarks & attendees introduction	Vitaly Omelyanovskiy , MD, PhD, DSc, Professor, President, ISPOR Russia HTA Chapter, Director, FSBI «Center of comprehensive assessment in healthcare» of the Ministry of health of the Russian Federation, Director, Center for HTA, RANEPА
16:40-16:55	Modeling the inclusion of drugs in the Russian government's reimbursement lists. An analysis of the 2014 data	Alexey Kolbin , MD, PhD, DSc, Professor, Head of the Department of Clinical Pharmacology, First Pavlov State Medical University of St. Petersburg, President, ISPOR Russia St. Petersburg Chapter
16:55-17:10	Russian vital and essential drugs list: the role of clinical pharmacology and pharmacoconomics in the development of procedure for selecting drugs	Maxim Frolov , MD, PhD, Volgograd State Medical University, Russian Interregional non-profit organization «Association of clinical pharmacologists»
17:10-17:25	Can MCDA be helpful in elaborating decision rules on reimbursement?	Olga Rebrova , MD, PhD, DSc, Professor, Center for HTA, RANEPА
17:25-17:40	Essential drug list as a basis for pricing. Is there a place for risk-sharing agreement?	Vasily Ryazhenov , PharmD, PhD, MBA, Head of task group for the economic evaluation of healthcare technologies (The State Duma of the Russian Federation), I.M. Sechenov First Moscow State Medical University, Moscow, Head of Center for strategic research in healthcare
17:40-17:55	Analysis of drug consumption in Russian outpatients with breast cancer whose treatment is funded by federal and regional healthcare budgets	Elena Derkach , MD, PhD, Center for HTA, RANEPА
17:55-18:10	New directions for the development of assessment of medical technologies in the Republic of Belarus	Elena Verich , vice-chairman of the Center for pharmaco-economic research and health technology assessment under the Union «Medicine and Pharmaceutics - innovative projects»
18:10-18:20	Discussion	All Attendees
18:20-18:30	Closing remarks & group photo	Vitaly Omelyanovskiy , MD, PhD, DSc, Professor, President, ISPOR Russia HTA Chapter, Director, FSBI «Center of comprehensive assessment in healthcare» of the Ministry of health of the Russian Federation, Director, Center for HTA, RANEPА